Study of autocorrelations and uncertainties applied to patients with Parkinson’s disease.

Publication date: Mar 24, 2025

The control of Levodopa (L-dopa) in Parkinson’s patients receiving chronic deep brain electrical stimulation (with an implant of an electrode into sub-cortical structures) will be studied here. Our main objective is to apply the Detrended Fluctuation Analysis (DFA) method and Shannon Entropy (H) in order to study the speed of tremor recorded in 16 patients with Parkinson’s disease. These Parkinson’s patients were divided into two groups (High Amplitude tremor and Low Amplitude tremor), and basically with two conditions of deep brain stimulation (on-off) and two conditions of L-dopa (on-off). These conditions (on-off) have a clear influence on the [Formula: see text] exponent and the Shannon Entropy respectively. In this sense, the auto-correlation exponent gives us information whether or not there is persistence in the signal produced by the Parkinsonian rest tremor, mainly differentiating those in Low and High Amplitude, or even identifying behavior change with a typical time scale. However, the Shannon Entropy gives us information about the uncertainty in the position of Parkinsonian rest tremor. In this way, a high value of H informs us that we have a high uncertainty in the signal of this tremor. Therefore, by combining these two techniques we have a better view of the (signal/noise) effects of deep brain stimulation and L-dopa (medication) in all patients with Parkinson’s disease, and thus helping to make a better analysis of this health problem, and with the possibility of supplementation in the Unified Parkinson’s Disease Rating Scale and Tremor Rating Scale, identifying fluctuation patterns on different time scales, the nature of the tremor, and its evolution over time.

Open Access PDF

Concepts Keywords
Auto Aged
Clinical Antiparkinson Agents
Deep Antiparkinson Agents
Disease Deep Brain Stimulation
Parkinsonian Detrended fluctuation analysis
Entropy
Female
Humans
L-dopa
Levodopa
Levodopa
Male
Middle Aged
Parkinson Disease
Tremor
Uncertainty

Semantics

Type Source Name
disease MESH Parkinson’s disease
drug DRUGBANK Levodopa
disease MESH tremor
disease MESH uncertainty
drug DRUGBANK Tropicamide
disease MESH neurological disorders
disease MESH movement disorders
drug DRUGBANK Coenzyme M
disease MESH dyskinesias
drug DRUGBANK Aspartame
drug DRUGBANK Propofol
drug DRUGBANK Fentanyl
pathway KEGG Parkinson disease
disease MESH parkinsonism
disease MESH epilepsy
disease MESH Amyotrophic Lateral Sclerosis
pathway KEGG Amyotrophic lateral sclerosis
disease MESH gait
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *